Featured Editorial
Why Is It So Difficult To Implement New Technologies?
By Ed Miseta, Chief Editor, Clinical Leader

For many companies, implementing new clinical technologies can be a difficult endeavor. Compatibility issues, training, and employees who are resistant to change can make implementations a challenge. What can executives do to better prepare for change when it comes to their companies?

Do Your Clinical Trials Suffer From Adoptaphobia Syndrome?
By Débora S. Araujo, Associate Director, Site Budgets and Payments, Boehringer Ingelheim Pharmaceuticals, Inc.

Despite the focus on innovation at conferences, TED talks, and other forums in the last few years, as an industry we are still very slow to innovate and even slower to adopt new technologies, best practices, and methods. This intense fear of adoption in our industry is what I affectionately call “adoptaphobia.” Adoptaphobia refers to our industry’s fear of and reluctance to adopt new initiatives, best practices, and technologies to create efficiencies and reduce redundancies. We love to talk about issues and deliberate and discuss new methods, but we are extremely slow to commit and adopt the recommendations and methods that we agree would make everyone’s lives easier and streamline processes.

BMS Invests Record $3.6 Billion In Immuno-Oncology Pathway
By Ed Miseta, Chief Editor, Clinical Leader

Bristol-Myers Squibb (BMS) and Nektar Therapeutics have announced a partnership deal worth up to $3.6 billion that will lay out a new path for immuno-oncology (I/O) combination therapies.

Industry Insights
Craftsmanship In Clinical Trial Study Design
Article | By Ryan Bailey, MA, and Shann Williams, Rho

To be a successful clinical researcher, you need to coalesce expertise across a variety of domains — statistics, data management, project management, clinical operations, product safety, regulatory, medical writing — as you design, prepare, execute, and troubleshoot throughout the trial.

Myopic Focus On Dashboards May Blur Clinical Trial Insights
Guest Column | By Craig Morgan, goBalto

There is intense pressure to speed clinical trials and restrain costs. Given the burden of this duality clinical project managers are expected to make smarter decisions on intelligence derived from clinical trial data at a faster pace, while sponsors and contract research organizations (CROs) are looking for ways to incorporate business intelligence (BI) into the eClinical systems they are using to empower oversight and turn raw trial data into actionable information.

Advancing Clinical Study Execution And Expediting Clinical Supplies
Q&A | PCI Pharma Services

The shift toward biologics, globalization of clinical trials, and regulatory and commercial pressures has placed new stresses on clinical supply chains.

Improved Data Quality And Integrity For Faster Regulatory Approvals
White Paper | Medidata Solutions

A study examining all new molecular entity (NME) applications first submitted to the FDA between 2000 and 2012 found that several potentially preventable deficiencies account for significant delays in the approval of new drugs.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.

Connect With Clinical Leader:
   LinkedIn    Twitter